<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365166">
  <stage>Registered</stage>
  <submitdate>18/10/2013</submitdate>
  <approvaldate>31/10/2013</approvaldate>
  <actrnumber>ACTRN12613001200774</actrnumber>
  <trial_identification>
    <studytitle>The Effect of Zinc Supplementation on Expression of Zinc Transporters in Healthy Individuals </studytitle>
    <scientifictitle>The Effect of Zinc Supplementation on Expression of Zinc Transporters in Healthy Individuals</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Zinc transport</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Zinc Chelate 220mg (22mg elemental zinc), one tablet per day for 21 days administered orally (TGA registry - ARTG 128690). Compliance will be checked by tablet return and plasma zinc levels. 
</interventions>
    <comparator>No treatment</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Zinc transporter mRNA expression in peripheral blood mononuclear cells by real-time quantitative PCR </outcome>
      <timepoint>22 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Inflammation (CRP, IL-1, IL6, TNF-alpha) by rate nephelometry or similar</outcome>
      <timepoint>22 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma zinc by ICP-MS</outcome>
      <timepoint>22 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Adults, age 18-65 y
- Have not been diagnosed with major illness
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>- Diagnosis of major illness
- Taking of prescription drugs which known to interact with zinc
- Women who are pregnant or breastfeeding </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by computer</concealment>
    <sequence>Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation) </sequence>
    <masking />
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods>The sample size for this study is 40. There is no literature on zinc transporter expression under these intervention conditions. We feel a sample size of 40 is reasonable for a pilot study. </statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/10/2013</anticipatedstartdate>
    <actualstartdate>1/10/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>18/03/2014</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress>The University of Sydney 
NSW 2006</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Meat and Livestock Australia</fundingname>
      <fundingaddress>Level 1, 40 Mount Street, North Sydney NSW 2060</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Sub-groups of the Australian population are considered at risk of zinc deficiency but uncertainty remains
in the interpretation of zinc biomarkers. Zinc has no definable, accessible body stores. Our proposal aims
to explore the usefulness of zinc transporters, which regulate the movement of zinc into and within-cells,
as potential biomarkers of zinc status in humans. We aim to examine the feasibility of using peripheral blood mononuclear cells for the assessment of zinc status. If our
approach is successful we will have the potential of investigating zinc status in greater detail.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Sydney HREC </ethicname>
      <ethicaddress>Level 2, Margaret Telfer
The University of Sydney
NSW 2006 Australia</ethicaddress>
      <ethicapprovaldate>4/08/2013</ethicapprovaldate>
      <hrec>2012/370</hrec>
      <ethicsubmitdate>10/09/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Samir Samman</name>
      <address>Rm 475, Biochemistry Building G08 
The University of Sydney  
NSW 2006</address>
      <phone>+61 2 9351 2476</phone>
      <fax />
      <email>samir.samman@sydney.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Samir Samman</name>
      <address>Rm 475, Biochemistry Building G08 
The University of Sydney  
NSW 2006</address>
      <phone>+61 2 9351 2476</phone>
      <fax />
      <email>samir.samman@sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Samir Samman</name>
      <address>Rm 475, Biochemistry Building G08 
The University of Sydney  
NSW 2006</address>
      <phone>+61 2 9351 2476</phone>
      <fax />
      <email>samir.samman@sydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>